1. Home
  2. VSTD vs ENSC Comparison

VSTD vs ENSC Comparison

Compare VSTD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSTD

Vestand Inc.

N/A

Current Price

$0.23

Market Cap

6.3M

ML Signal

N/A

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.09

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTD
ENSC
Founded
2016
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
6.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VSTD
ENSC
Price
$0.23
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
659.1K
418.0K
Earning Date
03-27-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,902,861.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.39
1.51
52 Week Low
$0.20
$1.08
52 Week High
$5.63
$9.88

Technical Indicators

Market Signals
Indicator
VSTD
ENSC
Relative Strength Index (RSI) N/A 27.48
Support Level N/A $1.08
Resistance Level N/A $1.24
Average True Range (ATR) 0.00 0.13
MACD 0.00 -0.01
Stochastic Oscillator 0.00 1.75

Price Performance

Historical Comparison
VSTD
ENSC

About VSTD Vestand Inc.

Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: